Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsStanich, Peter P
Gossard, Andrea A
Lindor, Keith D
MetadataShow full item record
CitationDig Liver Dis. 2011, 43(4):309-13
AbstractBACKGROUND: Primary sclerosing cholangitis results in elevated but fluctuating serum alkaline phosphatase levels that occasionally return to normal. AIMS: To investigate the frequency of normalization of alkaline phosphatase in newly diagnosed primary sclerosing cholangitis patients and the subsequent clinical outcomes. METHODS: Records of newly diagnosed primary sclerosing cholangitis patients were examined retrospectively for laboratory values and clinical end points (cholangiocarcinoma, liver transplantation and death) within 10 years of diagnosis. Data from a recent prospective ursodeoxycholic acid treatment trial were also studied. RESULTS: Eighty-seven patients met the inclusion criteria. Normalization of alkaline phosphatase was seen in 35 (40%) patients. Five (14%) patients with normalization reached an end point whereas 17 (33%) of the patients with persistent elevation reached an end point (P=0.02). Ursodeoxycholic acid was used similarly by both groups. When the investigative criteria were applied to a prospective trial, there was again a significant relationship between normalization of alkaline phosphatase and survival in patients receiving ursodeoxycholic acid (P<0.01) and the placebo group (P=0.02). CONCLUSIONS: Serum alkaline phosphatase was found to normalize in a high proportion of newly diagnosed primary sclerosing cholangitis patients. This was significantly associated with a better prognosis in a retrospective cohort and when data from a prospective treatment trial was evaluated.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
- Authors: Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH
- Issue date: 2016 Mar-Apr
- Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
- Authors: Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A
- Issue date: 2013 Jul
- Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
- Authors: Al Mamari S, Djordjevic J, Halliday JS, Chapman RW
- Issue date: 2013 Feb
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
- Authors: Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F
- Issue date: 2009 Sep
- Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
- Authors: Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G
- Issue date: 1992 Sep